ID: ALA5285433

Max Phase: Preclinical

Molecular Formula: C27H32N4O5

Molecular Weight: 492.58

Representations

Canonical SMILES:  CCC(=O)CCCCC[C@H](NC(=O)C1CNC(=O)C1)c1ncc(-c2cc3ccccc3nc2OC)o1

Standard InChI:  InChI=1S/C27H32N4O5/c1-3-19(32)10-5-4-6-12-22(30-25(34)18-14-24(33)28-15-18)27-29-16-23(36-27)20-13-17-9-7-8-11-21(17)31-26(20)35-2/h7-9,11,13,16,18,22H,3-6,10,12,14-15H2,1-2H3,(H,28,33)(H,30,34)/t18?,22-/m0/s1

Standard InChI Key:  OBXDPJWJEONRBU-YSYXNDDBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 492.58

Molecular Weight (Monoisotopic): 492.2373

AlogP: 4.12

#Rotatable Bonds: 12

Polar Surface Area: 123.42

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.42

CX Basic pKa: 1.52

CX LogP: 2.70

CX LogD: 2.70

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.36

Np Likeness Score: -0.21

References

1. Bresciani A, Ontoria JM, Biancofiore I, Cellucci A, Ciammaichella A, Di Marco A, Ferrigno F, Francone A, Malancona S, Monteagudo E, Nizi E, Pace P, Ponzi S, Rossetti I, Veneziano M, Summa V, Harper S..  (2019)  Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.,  10  (4): [PMID:30996783] [10.1021/acsmedchemlett.8b00517]

Source

Source(1):

• Scientific Literature